2347 related articles for article (PubMed ID: 19880497)
21. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with
Lin Y; Wang Y; Zheng Y; Wang Z; Wang Y; Wang S
Hematology; 2020 Dec; 25(1):446-456. PubMed ID: 33250015
[No Abstract] [Full Text] [Related]
22. Acute Myeloid Leukemia, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology.
Tallman MS; Wang ES; Altman JK; Appelbaum FR; Bhatt VR; Bixby D; Coutre SE; De Lima M; Fathi AT; Fiorella M; Foran JM; Hall AC; Jacoby M; Lancet J; LeBlanc TW; Mannis G; Marcucci G; Martin MG; Mims A; O'Donnell MR; Olin R; Peker D; Perl A; Pollyea DA; Pratz K; Prebet T; Ravandi F; Shami PJ; Stone RM; Strickland SA; Wieduwilt M; Gregory KM; ; Hammond L; Ogba N
J Natl Compr Canc Netw; 2019 Jun; 17(6):721-749. PubMed ID: 31200351
[TBL] [Abstract][Full Text] [Related]
23. Postremission therapy with repeated courses of high-dose cytarabine, idarubicin, and limited autologous stem cell support achieves a very good long-term outcome in European leukemia net favorable and intermediate-risk acute myeloid leukemia.
Borlenghi E; Cattaneo C; Cerqui E; Archetti S; Bertoli D; Bellotti D; Gramegna D; Soverini G; Oberti M; Schieppati F; Pagani C; Passi A; Sciumé M; Farina M; Carbone C; Crippa C; Dalceggio D; Tucci A; Rossi G
Hematol Oncol; 2020 Dec; 38(5):754-762. PubMed ID: 32950042
[TBL] [Abstract][Full Text] [Related]
24. Familial myelodysplastic syndrome/acute myeloid leukemia.
Churpek JE
Best Pract Res Clin Haematol; 2017 Dec; 30(4):287-289. PubMed ID: 29156196
[TBL] [Abstract][Full Text] [Related]
25. [Acute leukemia in adults].
Eigendorff E; Hochhaus A
Pathologe; 2015 Sep; 36(5):503-17; quiz 518-9. PubMed ID: 26314268
[TBL] [Abstract][Full Text] [Related]
26. NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021.
Pollyea DA; Bixby D; Perl A; Bhatt VR; Altman JK; Appelbaum FR; de Lima M; Fathi AT; Foran JM; Gojo I; Hall AC; Jacoby M; Lancet J; Mannis G; Marcucci G; Martin MG; Mims A; Neff J; Nejati R; Olin R; Percival ME; Prebet T; Przespolewski A; Rao D; Ravandi-Kashani F; Shami PJ; Stone RM; Strickland SA; Sweet K; Vachhani P; Wieduwilt M; Gregory KM; Ogba N; Tallman MS
J Natl Compr Canc Netw; 2021 Jan; 19(1):16-27. PubMed ID: 33406488
[TBL] [Abstract][Full Text] [Related]
27. Management of acute promyelocytic leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.
Sanz MA; Grimwade D; Tallman MS; Lowenberg B; Fenaux P; Estey EH; Naoe T; Lengfelder E; Büchner T; Döhner H; Burnett AK; Lo-Coco F
Blood; 2009 Feb; 113(9):1875-91. PubMed ID: 18812465
[TBL] [Abstract][Full Text] [Related]
28. Prognostic impact of the European LeukemiaNet standardized reporting system in older AML patients receiving stem cell transplantation after non-myeloablative conditioning.
Bill M; Jentzsch M; Grimm J; Schubert K; Lange T; Cross M; Behre G; Vucinic V; Pönisch W; Franke GN; Niederwieser D; Schwind S
Bone Marrow Transplant; 2017 Jun; 52(6):932-935. PubMed ID: 28368377
[No Abstract] [Full Text] [Related]
29. Evaluation of the proposed reporting system of the European LeukemiaNet and recommendations for prognosis of acute myeloid leukemia.
Alpermann T; Kern W; Schnittger S; Schmid C; Kreuzer KA; Serve H; Pielken HJ; Schmitz N; Wendtner CM; Haferlach C; Haferlach T
Leuk Res; 2013 Feb; 37(2):197-200. PubMed ID: 23237559
[TBL] [Abstract][Full Text] [Related]
30. [Clinical and biological prognostic factors in relapsed acute myeloid leukemia patients].
Yébenes-Ramírez M; Serrano J; Martínez-Losada C; Sánchez-García J
Med Clin (Barc); 2016 Sep; 147(5):185-191. PubMed ID: 27374030
[TBL] [Abstract][Full Text] [Related]
31. Interest of cytogenetic and FISH evaluation for prognosis evaluation in 198 patients with acute myeloid leukemia in first complete remission in a single institution.
Hirsch P; Labopin M; Viguié F; Perot C; Isnard F; Mamez AC; Bilhou-Nabera C; Marzac C; Delhommeau F; Lapusan S; Marie JP; Mohty M; Legrand O
Leuk Res; 2014 Aug; 38(8):907-12. PubMed ID: 24957411
[TBL] [Abstract][Full Text] [Related]
32. How I treat acute myeloid leukemia.
Rowe JM; Tallman MS
Blood; 2010 Oct; 116(17):3147-56. PubMed ID: 20558611
[TBL] [Abstract][Full Text] [Related]
33. Incorporation of long non-coding RNA expression profile in the 2017 ELN risk classification can improve prognostic prediction of acute myeloid leukemia patients.
Tsai CH; Yao CY; Tien FM; Tang JL; Kuo YY; Chiu YC; Lin CC; Tseng MH; Peng YL; Liu MC; Liu CW; Yao M; Lin LI; Chou WC; Chen CY; Hou HA; Tien HF
EBioMedicine; 2019 Feb; 40():240-250. PubMed ID: 30662003
[TBL] [Abstract][Full Text] [Related]
34. Secondary Adult Acute Myeloid Leukemia: a Review of Our Evolving Understanding of a Complex Disease Process.
Zeichner SB; Arellano ML
Curr Treat Options Oncol; 2015 Aug; 16(8):37. PubMed ID: 26143266
[TBL] [Abstract][Full Text] [Related]
35. Incorporating measurable ('minimal') residual disease-directed treatment strategies to optimize outcomes in adults with acute myeloid leukemia.
Pettit K; Stock W; Walter RB
Leuk Lymphoma; 2016 Jul; 57(7):1527-33. PubMed ID: 27269126
[TBL] [Abstract][Full Text] [Related]
36. [Necessity of Genetic Examination in Treatment for Hematological Malignancies].
Kiyoi H
Rinsho Byori; 2015 Mar; 63(3):369-76. PubMed ID: 26524860
[TBL] [Abstract][Full Text] [Related]
37. Clinical impact of KMT2C and SPRY4 expression levels in intensively treated younger adult acute myeloid leukemia patients.
Kayser S; Feszler M; Krzykalla J; Schick M; Kramer M; Benner A; Thol F; Platzbecker U; Müller-Tidow C; Ho AD; Ehninger G; Heuser M; Schlenk RF; Thiede C; Röllig C; Krämer A
Eur J Haematol; 2017 Dec; 99(6):544-552. PubMed ID: 28940816
[TBL] [Abstract][Full Text] [Related]
38. [Progress in the diagnosis and treatment of childhood AML].
Adachi S
Rinsho Ketsueki; 2015 Oct; 56(10):2220-9. PubMed ID: 26458463
[TBL] [Abstract][Full Text] [Related]
39. How Precision Medicine Is Changing Acute Myeloid Leukemia Therapy.
Heuser M; Mina A; Stein EM; Altman JK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():411-420. PubMed ID: 31099617
[TBL] [Abstract][Full Text] [Related]
40. Using minimal (measurable) residual disease assessments to guide decision-making for timing of allogeneic transplantation in acute myeloid leukemia.
Fasan O
Curr Opin Hematol; 2019 Nov; 26(6):413-420. PubMed ID: 31503019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
